About us
CARE-DNA IP is a Danish spin out, founded in 2024, based on 8 years of research and 7.8 million € of funding in analysis of circular DNA from the Regenberg Lab at the University of Copenhagen. We aim to offer a first in class screening solution for detection of pancreatic cancer and other hard to detect cancers.
Our goal
The average survival rate of pancreatic cancer (PDAC) today is <13% driven by late-stage detection due to the asymptomatic nature of the disease. Most patients are diagnosed when they present symptoms like jaundice, rapid weight loss, and abdominal pain which characterizes stage IV with a survival rate of less than 4%.
Patients that are diagnosed earlier have better options for both surgery and chemotherapy. However, these patients are mostly diagnosed through tests for other diseases than PDAC.
Our goal is to provide a non-invasive, sensitive, and specific test for early detection of PDAC and other hard to detect cancers. This solution will allow for efficient treatment, because patients can now be treated in early stages, where survival rates can increase to more than 80%, leading to hundreds of thousands of lives being saved annually.
Our test will be a fully clinically implementable, IVDR-approved diagnostic tool designed to test suspicions of a range of cancers.
